Ultrasensitive ImmunoMag-CRISPR Lateral Flow Assay for Point-of-Care Testing of Urinary Biomarkers
ACS Sensors · 26.01.2024 · 9 (1) · 92-100
DOI: 10.1021/acssensors.3c01694 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, online erschienen am 23.12.2023. Verfasst von Inseon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, and Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 Ei…. Hauptthemen laut MEDLINE: Point-of-Care Testing. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Rapid, accurate, and noninvasive detection of biomarkers in saliva, urine, or nasal fluid is essential for the identification, early diagnosis, and monitoring of cancer, organ failure, transplant rejection, vascular diseases, autoimmune disorders, and infectious diseases. We report the development of an Immuno-CRISPR-based lateral flow assay (LFA) using antibody-DNA barcode complexes with magnetic enrichment of the target urinary biomarkers CXCL9 and CXCL10 for naked eye detection (ImmunoMag-CRISPR LFA). An intermediate approach involving a magnetic bead-based Immuno-CRISPR assay (ImmunoMag-CRISPR) resulted in a limit of detection (LOD) of 0.6 pg/mL for CXCL9. This value surpasses the detection limits achieved by previously reported assays. The highly sensitive detection method was then re-engineered into an LFA format with an LOD of 18 pg/mL for CXCL9, thereby enabling noninvasive early detection of acute kidney transplant rejection. The ImmunoMag-CRISPR LFA was tested on 42 clinical urine samples from kidney transplant recipients, and the assay could determine 11 positive and 31 negative urinary samples through a simple visual comparison of the test line and the control line of the LFA strip. The LFA system was then expanded to quantify the CXCL9 and CXCL10 levels in clinical urine samples from images. This approach has the potential to be extended to a wide range of point-of-care tests for highly sensitive biomarker detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biological Engineering, and Center for Biotechnology & Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 Eighth Street, Troy, New York 12180, United States.
- Comprehensive Transplant Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States.
ORCID-Profile: Jonathan S Dordick
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Lee, I., Kwon, S. J., Heeger, P., & Dordick, J. S. (2024). Ultrasensitive ImmunoMag-CRISPR Lateral Flow Assay for Point-of-Care Testing of Urinary Biomarkers. ACS Sensors, 9(1), 92-100. https://doi.org/10.1021/acssensors.3c01694
Vancouver
Lee I, Kwon SJ, Heeger P, Dordick JS. Ultrasensitive ImmunoMag-CRISPR Lateral Flow Assay for Point-of-Care Testing of Urinary Biomarkers. ACS Sensors. 2024;9(1):92-100. doi:10.1021/acssensors.3c01694
BibTeX
@article{Lee2024,
author = {Lee, Inseon and Kwon, Seok-Joon and Heeger, Peter and Dordick, Jonathan S},
title = {Ultrasensitive ImmunoMag-CRISPR Lateral Flow Assay for Point-of-Care Testing of Urinary Biomarkers},
journal = {ACS Sensors},
year = {2024},
volume = {9},
number = {1},
pages = {92--100},
doi = {10.1021/acssensors.3c01694}
}
EUVIMED